YTEN Company Profile and Key Details

Q: Who are the executives of YTEN?

Dr. Nicholas Renegar Ph.D.Director of Bus. Analytics & OperationsDr. Oliver P. PeoplesCo-Founder, Pres, Chief Executive Officer & DirectorDr. Kristi D. SnellVice President of Research & Chief Science OfficerMr. Charles B. HaaserVice President of Fin., Chief Accounting Officer & TreasurerMs. Lynne H. BrumVice President of Planning & Corporation Communications and Sec.Dr. Oliver P. Peoples Ph.D.Co-Founder, Pres, Chief Executive Officer & DirectorDr. Anthony J. Sinskey Ph.D., Sc.D.Co-Founder and Scientific Advisor

NASDAQ : YTEN

Yield10 Bioscience

$0.34

-0.3598-51.78%

At Close 4:00 PM

Not Actively Trading

67.02

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Yield10 Bioscience, Inc. (YTEN) stock declined over -51.78%, trading at $0.34 on NASDAQ, down from the previous close of -. The stock opened at $0.69, fluctuating between $0.34 and $0.69 in the recent session.

Stock Snapshot

N/A

Prev. Close

345.46K

Market Cap

0.33505

Day Low

-0.01663604766633565

P/E Ratio

-20.14

EPS (TTM)

-0.84

Cash Flow per Share

0.69

Open

1.03M

Number of Shares

0.6949

Day High

52.13%

Free Float in %

-0.21

Book Value

11.43K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 17, 2025	0.00	0.00	0.00	0.00	0
Jan 16, 2025	0.00	0.00	0.00	0.00	1.41K
Jan 15, 2025	0.10	0.10	0.10	0.10	0
Jan 14, 2025	0.18	0.18	0.10	0.10	25.57K
Jan 13, 2025	0.25	0.25	0.21	0.21	12.28K
Jan 10, 2025	0.25	0.25	0.21	0.21	19.82K
Jan 08, 2025	0.28	0.28	0.28	0.28	0
Jan 07, 2025	0.28	0.28	0.28	0.28	0
Jan 06, 2025	0.35	0.35	0.27	0.28	7.85K
Jan 03, 2025	0.35	0.35	0.35	0.35	1.08K
Jan 02, 2025	0.20	0.37	0.20	0.35	11.64K
Dec 31, 2024	0.36	0.36	0.31	0.31	2.2K
Dec 30, 2024	0.32	0.35	0.32	0.35	1.25K
Dec 27, 2024	0.40	0.40	0.40	0.40	730
Dec 26, 2024	0.32	0.36	0.32	0.36	2.51K
Dec 24, 2024	0.34	0.34	0.34	0.34	453
Dec 23, 2024	0.32	0.36	0.32	0.33	1.11K
Dec 20, 2024	0.34	0.34	0.34	0.34	0
Dec 19, 2024	0.34	0.34	0.34	0.34	684
Dec 18, 2024	0.32	0.34	0.32	0.34	1.03K

Contact Details

Woburn, MA 01801

United States

https://www.yield10bio.com 617 583 1700

About Company

Yield10 Bioscience, Inc. is an agricultural biotechnology firm dedicated to creating advanced solutions that can significantly boost crop productivity across the United States and Canada. Utilizing its proprietary Trait Factory – an innovative gene discovery platform – the company develops enhanced varieties of oilseed Camelina sativa for exclusive seed products. Additionally, it identifies valuable genetic characteristics applicable to both the agricultural and food sectors. Yield10 Bioscience maintains licensing agreements with several key industry players, including GDM Seeds, J. R. Simplot, Forage Genetics International, LLC, and Bayer AG. The company, incorporated in 1992, rebranded from Metabolix, Inc. to Yield10 Bioscience, Inc. in January 2017. Its corporate headquarters are located in Woburn, Massachusetts.

Stock Peers

NXTS

0.08+2.14%

Nexentis Technologies Inc.$3.81 FMTO

Femto Technologies Inc.$3.61 BHST

-0.1-3.50%

BioHarvest Sciences Inc. Common Stock$2.76 SVFD

-0.01-0.70%

Save Foods, Inc.$1.41 SEED

-0.0099-0.98%

Origin Agritech Limited$1.00 AFRIW

-0.05-6.67%

Forafric Global PLC$0.70 RKDA

-0.0078-1.14%

Arcadia Biosciences, Inc.$0.68 BIOX

0.0056+1.70%

Bioceres Crop Solutions Corp.$0.34 LVRO

Lavoro Limited$0.13

Company Overview

The stock is currently mid-range between its 52-week high and low $0.24 and $17.26. With a market capitalization of about $345.46 thousand, Yield10 Bioscience, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.43). Key stats such as the average daily volume over the past year has been around 5.09 thousand shares, trading with heavier-than-usual volume. Headquartered in Woburn, MA, Yield10 Bioscience, Inc. operates in the Basic Materials sector and the Agricultural Inputs industry. Led by CEO Oliver P. Peoples, the company employs approximately 29 people and listed since November 10, 2006. Yield10 Bioscience, Inc. is an agricultural biotechnology firm dedicated to creating advanced solutions that can significantly boost crop productivity across the United States and Canada.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -55.01%, SMA50 -63.9%, SMA200 -70.5%). The stock’s 14-day RSI is 27.6 (weak momentum), while the ATR of 1.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.81% below its high and over 18.5% above its low.

Valuation Metrics

Yield10 Bioscience, Inc. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 5.76 and a price-to-book ratio of -0.04 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.03, also below market averages.

Dividend & Fair Value

Yield10 Bioscience, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.29. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Yield10 Bioscience, Inc. generated EPS of -$50.04 over the past year. Five-year average earnings growth is 45.25%. Wall Street analysts project EPS growth of 0.0% annually over the next five years. Yield10 Bioscience, Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2024, missed forecasts by -99.87%. The prior quarter beat by -99.82%. Over the last six quarters, Apple has recorded several small beats. These include 33.33% in August 14, 2023.

Shareholding & Insider Activity

Yield10 Bioscience, Inc. has 692.68 thousand shares outstanding. The public float is 537.50 thousand shares, elevated short interest at 0.45% of float. This equals 2.53 thousand shares. The short ratio is 0.03 days. Institutional investors hold 0.04% of the float. Insiders own 17.55%. SCULLY WILLIAM P holds 2.93 million shares, Peoples Oliver P has 67.63 thousand shares and SCHULER JACK W has 63.79 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Yield10 Bioscience generated $60.00K in revenue, or $0.01 per share. Gross margin was -383.33%, operating margin -24028.33%, and net profit margin -24091.67%. Returns are negative, with ROA at -369.98% and ROE at 582.16%.
On valuation metrics, Yield10 Bioscience trades at a P/E of -0.01, P/S of 5.76 and P/B of -0.04. Liquidity is tight, with a current ratio of 0.29 and quick ratio of 0.29. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1512.86 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -1.29, supported by a cash flow-to-debt ratio of -3.14.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Yield10 Bioscience posted revenue of $60.00K, down slightly from $450.00K in the prior quarter. Gross profit was - $230.00K (margin -383.33%). Operating income was - $14.42M (margin -24028.3%). Net income was- $14.46M (EPS - $1.82).
The company ended the quarter with $1.07M in cash and short-term investments, a total debt of $3.18M, and net debt of $2.11M. Total assets were $3.91M, with equity of - $2.48M. Financials further reflected weakness, with operating cash flow of - $10.07M, free cash flow of - $10.11M, and capital expenditures of - $46.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Yield10 Bioscience, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4900.0%, with price expected at $0.05 by January 31, 2025, within a range of $0.00 to $0.20 3-Month Outlook: Projected rise of 226900.0%, reaching $2.27 by April 08, 2025, with a range of $0.00 to $5.43. 1-Year Outlook: Projected gain of 57900.0%, with price at $0.58 by January 09, 2026, within a range of $0.00 to $8.00.

Key Takeaways

Yield10 Bioscience, Inc. (NASDAQ:YTEN) shares are up 890.39% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Yield10 Bioscience, Inc. trading at a premium to the broader market with a P/E of -0.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.17, suggesting 1316900.0% upside. Our AI forecast model points to short-term strength (4900.0% over two weeks), a medium-term rise (226900.0% over three months), and a longer-term gain (57900.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Yield10 Bioscience, Inc. (YTEN) stock price?

Yield10 Bioscience, Inc. (NASDAQ: YTEN) stock price is $0.34 in the last trading session. During the trading session, YTEN stock reached the peak price of $0.69 while $0.34 was the lowest point it dropped to. The percentage change in YTEN stock occurred in the recent session was -51.78% while the dollar amount for the price change in YTEN stock was - $0.36.

YTEN's industry and sector of operation?

The NASDAQ listed YTEN is part of Agricultural Inputs industry that operates in the broader Basic Materials sector. Yield10 Bioscience, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of YTEN?

Dr. Nicholas Renegar Ph.D.
Director of Bus. Analytics & Operations
Dr. Oliver P. Peoples
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Kristi D. Snell
Vice President of Research & Chief Science Officer
Mr. Charles B. Haaser
Vice President of Fin., Chief Accounting Officer & Treasurer
Ms. Lynne H. Brum
Vice President of Planning & Corporation Communications and Sec.
Dr. Oliver P. Peoples Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Anthony J. Sinskey Ph.D., Sc.D.
Co-Founder and Scientific Advisor

How YTEN did perform over past 52-week?

YTEN's closing price is 42.45% higher than its 52-week low of $0.24 where as its distance from 52-week high of $17.26 is -98.06%.

How many employees does YTEN have?

Number of YTEN employees currently stands at 29.

Link for YTEN official website?

Official Website of YTEN is: https://www.yield10bio.com

How do I contact YTEN?

YTEN could be contacted at phone 617 583 1700 and can also be accessed through its website. YTEN operates from 19 Presidential Way, Woburn, MA 01801, United States.

How many shares of YTEN are traded daily?

YTEN stock volume for the day was 11.43K shares. The average number of YTEN shares traded daily for last 3 months was 5.09K.

What is the market cap of YTEN currently?

The market value of YTEN currently stands at $345.46K with its latest stock price at $0.34 and 1.03M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	29
Beta	1.43
Sales or Revenue	$60.00K
5Y Sales Change%	-0.997%
Fiscal Year Ends	December
Sector	Basic Materials
Industry	Agricultural Inputs

YTEN Company Profile and Key Details

Yield10 Bioscience

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook